Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEchothiophate
Identification
- Name
- Echothiophate
- Accession Number
- DB01057 (APRD00942)
- Type
- Small Molecule
- Groups
- Approved
- Description
A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
- Structure
Structure for DB01057 (Echothiophate)
- Synonyms
- 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodide
- Echothiophate
- Ecothiopate
- Ecothiopatum
- Phospholine
- External IDs
- MI 217
- Product Ingredients
Ingredient UNII CAS InChI Key Echothiophate iodide BA9QH3P00T 513-10-0 OVXQHPWHMXOFRD-UHFFFAOYSA-M - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Phospholine Iodide - Liq Pws 3mg/5ml Liquid; Powder, for solution 3 mg Ophthalmic Storz, Division Of Wyeth Ayerst Canada Inc. 1997-04-29 1999-08-12 Canada 
Phospholine Iodide - Pws 12.5mg/5ml Powder, for solution 12.5 mg Ophthalmic Storz, Division Of Wyeth Ayerst Canada Inc. 1997-08-29 1999-08-12 Canada Phospholine Iodide - Pws 6.25mg/5ml Powder, for solution 6.25 mg Ophthalmic Storz, Division Of Wyeth Ayerst Canada Inc. 1997-04-29 2000-08-02 Canada Phospholine Iodide 12.5mg/5ml Powder, for solution 12.5 mg Ophthalmic Wyeth Ayerst Canada Inc. 1994-12-31 2001-08-30 Canada Phospholine Iodide 3mg/5ml Powder, for solution 3 mg Ophthalmic Wyeth Ayerst Canada Inc. 1998-12-02 2001-05-07 Canada Phospholine Iodide 6.25mg/5ml Powder, for solution 6.25 mg Ophthalmic Wyeth Ayerst Canada Inc. 1999-10-06 2001-08-03 Canada Phospholine Iodide Ophthalmic Kit Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. 1959-12-04 Not applicable US 
Phospholine Iodide Pws 6.25mg/5ml Powder, for solution 6.25 mg Ophthalmic Wyeth Ayerst Canada Inc. 1994-12-31 1997-08-14 Canada - International/Other Brands
- Echodide (Alcon) / Phospholine Iodide (Wyeth-Ayerst)
- Categories
- Antiglaucoma Preparations and Miotics
- Autonomic Agents
- Cholinergic Agents
- Cholinesterase Inhibitors
- Enzyme Inhibitors
- Miotics
- Neurotransmitter Agents
- Ophthalmologicals
- Organophosphates
- Organophosphorus Compounds
- Organothiophosphates
- Organothiophosphorus Compounds
- Parasympathomimetics
- Peripheral Nervous System Agents
- Sensory Organs
- Sulfur Compounds
- UNII
- 0F350BVT6S
- CAS number
- 6736-03-4
- Weight
- Average: 256.323
Monoisotopic: 256.113625809 - Chemical Formula
- C9H23NO3PS
- InChI Key
- BJOLKYGKSZKIGU-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H23NO3PS/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5/h6-9H2,1-5H3/q+1
- IUPAC Name
- diethyl {[2-(trimethylazaniumyl)ethyl]sulfanyl}phosphonate
- SMILES
- CCOP(=O)(OCC)SCC[N+](C)(C)C
Pharmacology
- Indication
For use in the treatment of subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated.
- Associated Conditions
- Pharmacodynamics
Echothiophate Iodide is a potent, long-acting cholinesterase inhibitor used as a miotic in the treatment of glaucoma. Echothiophate iodide will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eyedrop therapy.
- Mechanism of action
Echothiophate Iodide is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. Echothiophate iodide binds irreversibly to cholinesterase, and is long acting due to the slow rate of hydrolysis by cholinesterase. It causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure, and potentiation of accommodation.
Target Actions Organism ACholinesterase inhibitorHuman - Absorption
This ophthalmic medication may be systemically absorbed.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Side effects include blurred vision or change in near or distant vision and eye pain. LD50: 174 mcg/kg in rats. (MSDS)
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Echothiophate. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Echothiophate. Experimental, Illicit Acebutolol Echothiophate may increase the bradycardic activities of Acebutolol. Approved, Investigational Acetylcholine The risk or severity of adverse effects can be increased when Echothiophate is combined with Acetylcholine. Approved Aclidinium The therapeutic efficacy of Aclidinium can be decreased when used in combination with Echothiophate. Approved Alclometasone The risk or severity of adverse effects can be increased when Alclometasone is combined with Echothiophate. Approved Alcuronium The therapeutic efficacy of Alcuronium can be decreased when used in combination with Echothiophate. Experimental Aldosterone The risk or severity of adverse effects can be increased when Aldosterone is combined with Echothiophate. Experimental, Investigational Alprenolol Echothiophate may increase the bradycardic activities of Alprenolol. Approved, Withdrawn Amcinonide The risk or severity of adverse effects can be increased when Amcinonide is combined with Echothiophate. Approved Amiodarone Echothiophate may increase the bradycardic activities of Amiodarone. Approved, Investigational Androstenedione The risk or severity of adverse effects can be increased when Androstenedione is combined with Echothiophate. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Anecortave is combined with Echothiophate. Investigational anecortave acetate The risk or severity of adverse effects can be increased when anecortave acetate is combined with Echothiophate. Investigational Anisotropine Methylbromide The therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Echothiophate. Approved Arecoline The risk or severity of adverse effects can be increased when Echothiophate is combined with Arecoline. Experimental Arotinolol Echothiophate may increase the bradycardic activities of Arotinolol. Investigational Asenapine Echothiophate may increase the bradycardic activities of Asenapine. Approved Atamestane The risk or severity of adverse effects can be increased when Atamestane is combined with Echothiophate. Investigational Atenolol Echothiophate may increase the bradycardic activities of Atenolol. Approved Atracurium The therapeutic efficacy of Atracurium can be decreased when used in combination with Echothiophate. Approved, Experimental, Investigational Atracurium besylate The therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Echothiophate. Approved Atropine The therapeutic efficacy of Atropine can be decreased when used in combination with Echothiophate. Approved, Vet Approved Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Echothiophate. Approved, Investigational Befunolol Echothiophate may increase the bradycardic activities of Befunolol. Experimental Benactyzine The therapeutic efficacy of Benactyzine can be decreased when used in combination with Echothiophate. Withdrawn Benzatropine The therapeutic efficacy of Benzatropine can be decreased when used in combination with Echothiophate. Approved Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Echothiophate. Approved, Vet Approved Betaxolol Echothiophate may increase the bradycardic activities of Betaxolol. Approved, Investigational Bethanechol The risk or severity of adverse effects can be increased when Echothiophate is combined with Bethanechol. Approved Bevantolol Echothiophate may increase the bradycardic activities of Bevantolol. Approved Biperiden The therapeutic efficacy of Biperiden can be decreased when used in combination with Echothiophate. Approved, Investigational Bisoprolol Echothiophate may increase the bradycardic activities of Bisoprolol. Approved Bopindolol Echothiophate may increase the bradycardic activities of Bopindolol. Approved Bornaprine The therapeutic efficacy of Bornaprine can be decreased when used in combination with Echothiophate. Experimental Bucindolol Echothiophate may increase the bradycardic activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Echothiophate. Approved Bufuralol Echothiophate may increase the bradycardic activities of Bufuralol. Experimental, Investigational Bupranolol Echothiophate may increase the bradycardic activities of Bupranolol. Approved Butylscopolamine The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Echothiophate. Approved, Investigational, Vet Approved Carbachol The risk or severity of adverse effects can be increased when Echothiophate is combined with Carbachol. Approved Carteolol Echothiophate may increase the bradycardic activities of Carteolol. Approved Carvedilol Echothiophate may increase the bradycardic activities of Carvedilol. Approved, Investigational Celiprolol Echothiophate may increase the bradycardic activities of Celiprolol. Approved, Investigational Cevimeline The risk or severity of adverse effects can be increased when Echothiophate is combined with Cevimeline. Approved Chlorphenoxamine The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Echothiophate. Withdrawn Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Echothiophate. Approved, Investigational Clobetasol The risk or severity of adverse effects can be increased when Clobetasol is combined with Echothiophate. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Echothiophate. Approved Clobetasone The risk or severity of adverse effects can be increased when Clobetasone is combined with Echothiophate. Approved Clocortolone The risk or severity of adverse effects can be increased when Clocortolone is combined with Echothiophate. Approved Cloranolol Echothiophate may increase the bradycardic activities of Cloranolol. Experimental Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Echothiophate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Corticosterone is combined with Echothiophate. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Echothiophate. Approved, Investigational Cyclopentolate The therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Echothiophate. Approved Darifenacin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Echothiophate. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Deflazacort is combined with Echothiophate. Approved, Investigational Desipramine Echothiophate may increase the bradycardic activities of Desipramine. Approved, Investigational Desloratadine The therapeutic efficacy of Desloratadine can be decreased when used in combination with Echothiophate. Approved, Investigational Desonide The risk or severity of adverse effects can be increased when Desonide is combined with Echothiophate. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Echothiophate. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Echothiophate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Echothiophate. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Echothiophate. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Echothiophate. Vet Approved Dexetimide The therapeutic efficacy of Dexetimide can be decreased when used in combination with Echothiophate. Withdrawn Dicyclomine The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Echothiophate. Approved Diflorasone The risk or severity of adverse effects can be increased when Diflorasone is combined with Echothiophate. Approved Difluocortolone The risk or severity of adverse effects can be increased when Difluocortolone is combined with Echothiophate. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Difluprednate is combined with Echothiophate. Approved Diphenhydramine The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Echothiophate. Approved, Investigational Dipyridamole The therapeutic efficacy of Echothiophate can be decreased when used in combination with Dipyridamole. Approved Emepronium The therapeutic efficacy of Emepronium can be decreased when used in combination with Echothiophate. Experimental Epanolol Echothiophate may increase the bradycardic activities of Epanolol. Experimental Epibatidine The risk or severity of adverse effects can be increased when Echothiophate is combined with Epibatidine. Experimental Equilenin The risk or severity of adverse effects can be increased when Equilenin is combined with Echothiophate. Experimental Equilin The risk or severity of adverse effects can be increased when Equilin is combined with Echothiophate. Approved Esatenolol Echothiophate may increase the bradycardic activities of Esatenolol. Experimental Esmolol Echothiophate may increase the bradycardic activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Estrone is combined with Echothiophate. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Echothiophate. Approved Etanautine The therapeutic efficacy of Etanautine can be decreased when used in combination with Echothiophate. Experimental Ethopropazine The therapeutic efficacy of Ethopropazine can be decreased when used in combination with Echothiophate. Approved Etybenzatropine The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Echothiophate. Experimental Fesoterodine The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Echothiophate. Approved Flavoxate The therapeutic efficacy of Flavoxate can be decreased when used in combination with Echothiophate. Approved Fluasterone The risk or severity of adverse effects can be increased when Fluasterone is combined with Echothiophate. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Echothiophate. Approved, Investigational Flumethasone The risk or severity of adverse effects can be increased when Flumethasone is combined with Echothiophate. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Echothiophate. Approved, Investigational Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Echothiophate. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Echothiophate. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Fluocortolone is combined with Echothiophate. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Echothiophate. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Fluprednidene is combined with Echothiophate. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Echothiophate. Approved Flurandrenolide The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Echothiophate. Approved Fluticasone The risk or severity of adverse effects can be increased when Fluticasone is combined with Echothiophate. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Echothiophate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Echothiophate. Approved Formestane The risk or severity of adverse effects can be increased when Formestane is combined with Echothiophate. Approved, Investigational, Withdrawn Gallamine The therapeutic efficacy of Gallamine can be decreased when used in combination with Echothiophate. Experimental Gallamine Triethiodide The therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Echothiophate. Approved Glycopyrronium The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Echothiophate. Approved, Investigational, Vet Approved GTS-21 The risk or severity of adverse effects can be increased when Echothiophate is combined with GTS-21. Investigational Halcinonide The risk or severity of adverse effects can be increased when Halcinonide is combined with Echothiophate. Approved, Investigational, Withdrawn HE3286 The risk or severity of adverse effects can be increased when HE3286 is combined with Echothiophate. Investigational Homatropine The therapeutic efficacy of Homatropine can be decreased when used in combination with Echothiophate. Approved Hydrocortisone The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Echothiophate. Approved, Vet Approved Hyoscyamine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Echothiophate. Approved Indenolol Echothiophate may increase the bradycardic activities of Indenolol. Withdrawn Ipratropium The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Echothiophate. Approved Istaroxime The risk or severity of adverse effects can be increased when Istaroxime is combined with Echothiophate. Investigational Labetalol Echothiophate may increase the bradycardic activities of Labetalol. Approved Landiolol Echothiophate may increase the bradycardic activities of Landiolol. Investigational Levobetaxolol Echothiophate may increase the bradycardic activities of Levobetaxolol. Approved, Investigational Levobunolol Echothiophate may increase the bradycardic activities of Levobunolol. Approved Lobeline The risk or severity of adverse effects can be increased when Echothiophate is combined with Lobeline. Investigational Loteprednol The risk or severity of adverse effects can be increased when Loteprednol is combined with Echothiophate. Approved Mazaticol The therapeutic efficacy of Mazaticol can be decreased when used in combination with Echothiophate. Experimental ME-609 The risk or severity of adverse effects can be increased when ME-609 is combined with Echothiophate. Investigational Mecamylamine The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Echothiophate. Approved, Investigational Medrysone The risk or severity of adverse effects can be increased when Medrysone is combined with Echothiophate. Approved Melengestrol The risk or severity of adverse effects can be increased when Melengestrol is combined with Echothiophate. Vet Approved Mepindolol Echothiophate may increase the bradycardic activities of Mepindolol. Experimental Methacholine The risk or severity of adverse effects can be increased when Echothiophate is combined with Methacholine. Approved, Investigational Methantheline The therapeutic efficacy of Methantheline can be decreased when used in combination with Echothiophate. Approved, Investigational Methscopolamine The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Echothiophate. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Echothiophate. Approved, Vet Approved Methylscopolamine bromide The therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Echothiophate. Approved Metipranolol Echothiophate may increase the bradycardic activities of Metipranolol. Approved Metixene The therapeutic efficacy of Metixene can be decreased when used in combination with Echothiophate. Approved Metoprolol Echothiophate may increase the bradycardic activities of Metoprolol. Approved, Investigational Mivacurium Echothiophate may decrease the neuromuscular blocking activities of Mivacurium. Approved Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Echothiophate. Approved, Vet Approved Nadolol Echothiophate may increase the bradycardic activities of Nadolol. Approved NCX 1022 The risk or severity of adverse effects can be increased when NCX 1022 is combined with Echothiophate. Investigational Nebivolol Echothiophate may increase the bradycardic activities of Nebivolol. Approved, Investigational Nicotine The risk or severity of adverse effects can be increased when Echothiophate is combined with Nicotine. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Echothiophate. Investigational Orphenadrine The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Echothiophate. Approved Otilonium The therapeutic efficacy of Otilonium can be decreased when used in combination with Echothiophate. Experimental, Investigational Oxitropium The therapeutic efficacy of Oxitropium can be decreased when used in combination with Echothiophate. Investigational Oxprenolol Echothiophate may increase the bradycardic activities of Oxprenolol. Approved Oxybutynin The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Echothiophate. Approved, Investigational Oxyphenonium The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Echothiophate. Approved Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with Echothiophate. Approved Paramethasone The risk or severity of adverse effects can be increased when Paramethasone is combined with Echothiophate. Approved Penbutolol Echothiophate may increase the bradycardic activities of Penbutolol. Approved, Investigational Pentolinium The therapeutic efficacy of Pentolinium can be decreased when used in combination with Echothiophate. Approved Phenglutarimide The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Echothiophate. Experimental Pilocarpine The risk or severity of adverse effects can be increased when Echothiophate is combined with Pilocarpine. Approved, Investigational Pindolol Echothiophate may increase the bradycardic activities of Pindolol. Approved, Investigational Pipecuronium The therapeutic efficacy of Pipecuronium can be decreased when used in combination with Echothiophate. Approved Pirenzepine The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Echothiophate. Approved Platelet Activating Factor Echothiophate may increase the bradycardic activities of Platelet Activating Factor. Experimental Practolol Echothiophate may increase the bradycardic activities of Practolol. Approved Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Echothiophate. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Echothiophate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Prednicarbate is combined with Echothiophate. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Echothiophate. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Echothiophate. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Pregnenolone is combined with Echothiophate. Approved, Experimental, Investigational Procyclidine The therapeutic efficacy of Procyclidine can be decreased when used in combination with Echothiophate. Approved Propafenone Echothiophate may increase the bradycardic activities of Propafenone. Approved Propantheline The therapeutic efficacy of Propantheline can be decreased when used in combination with Echothiophate. Approved Propiverine The therapeutic efficacy of Propiverine can be decreased when used in combination with Echothiophate. Approved, Investigational Propranolol Echothiophate may increase the bradycardic activities of Propranolol. Approved, Investigational Quinidine The therapeutic efficacy of Quinidine can be decreased when used in combination with Echothiophate. Approved, Investigational Rapacuronium Echothiophate may decrease the neuromuscular blocking activities of Rapacuronium. Withdrawn Rimexolone The risk or severity of adverse effects can be increased when Rimexolone is combined with Echothiophate. Approved Scopolamine The therapeutic efficacy of Scopolamine can be decreased when used in combination with Echothiophate. Approved, Investigational Solifenacin The therapeutic efficacy of Solifenacin can be decreased when used in combination with Echothiophate. Approved Sotalol Echothiophate may increase the bradycardic activities of Sotalol. Approved Succinylcholine The serum concentration of Succinylcholine can be increased when it is combined with Echothiophate. Approved Talinolol Echothiophate may increase the bradycardic activities of Talinolol. Investigational Terbutaline Echothiophate may increase the bradycardic activities of Terbutaline. Approved Tertatolol Echothiophate may increase the bradycardic activities of Tertatolol. Experimental Timolol Echothiophate may increase the bradycardic activities of Timolol. Approved Tiotropium The therapeutic efficacy of Tiotropium can be decreased when used in combination with Echothiophate. Approved Tixocortol The risk or severity of adverse effects can be increased when Tixocortol is combined with Echothiophate. Approved, Withdrawn Tolterodine The therapeutic efficacy of Tolterodine can be decreased when used in combination with Echothiophate. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Echothiophate. Approved, Vet Approved Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Echothiophate. Approved Trimethaphan The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Echothiophate. Approved, Investigational Tropatepine The therapeutic efficacy of Tropatepine can be decreased when used in combination with Echothiophate. Experimental Tropicamide The therapeutic efficacy of Tropicamide can be decreased when used in combination with Echothiophate. Approved, Investigational Trospium The therapeutic efficacy of Trospium can be decreased when used in combination with Echothiophate. Approved Tubocurarine The therapeutic efficacy of Tubocurarine can be decreased when used in combination with Echothiophate. Approved Ulobetasol The risk or severity of adverse effects can be increased when Ulobetasol is combined with Echothiophate. Approved Umeclidinium The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Echothiophate. Approved Varenicline The risk or severity of adverse effects can be increased when Echothiophate is combined with Varenicline. Approved, Investigational Vecuronium The therapeutic efficacy of Vecuronium can be decreased when used in combination with Echothiophate. Approved - Food Interactions
- Not Available
References
- Synthesis Reference
Fitch, H.M.; U.S. Patent 2,911,430; November 3, 1959; assigned to Campbell Pharmaceuticals, Inc.
- General References
- Reddy RH: Echothiophate iodide: its use in accommodative esotropia (high Ac/A ratio). Indian J Ophthalmol. 1982 Jul;30(4):225. [PubMed:7166393]
- Schmidt KG, Horowitz Y, Buckman G, Segev E, Levinger E, Geyer O: Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma. Curr Eye Res. 2010 Aug;35(8):698-702. doi: 10.3109/02713681003794076. [PubMed:20673046]
- External Links
- Human Metabolome Database
- HMDB0015190
- KEGG Drug
- D02193
- KEGG Compound
- C06975
- PubChem Compound
- 10548
- PubChem Substance
- 46505944
- ChemSpider
- 10108
- ChEBI
- 4753
- ChEMBL
- CHEMBL1201341
- Therapeutic Targets Database
- DAP000962
- PharmGKB
- PA164743139
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Echothiophate
- ATC Codes
- S01EB03 — Ecothiopate
- FDA label
- Download (45 KB)
- MSDS
- Download (87.9 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Wyeth Pharmaceuticals
- Dosage forms
Form Route Strength Liquid; powder, for solution Ophthalmic 3 mg Powder, for solution Ophthalmic 12.5 mg Powder, for solution Ophthalmic 3 mg Kit Powder, for solution Ophthalmic 6.25 mg - Prices
Unit description Cost Unit Phospholine iodide 0.125% 16.09USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US2911430 No 1958-01-15 1978-01-15 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 124-124.5 Fitch, H.M.; U.S. Patent 2,911,430; November 3, 1959; assigned to Campbell Pharmaceuticals, Inc. water solubility Soluble Not Available logP -2.25 Not Available - Predicted Properties
Property Value Source Water Solubility 0.297 mg/mL ALOGPS logP -2.2 ALOGPS logP -3.1 ChemAxon logS -3 ALOGPS pKa (Strongest Basic) -8.2 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 35.53 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 78.14 m3·mol-1 ChemAxon Polarizability 27.65 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption - 0.7708 Blood Brain Barrier + 0.91 Caco-2 permeable + 0.5098 P-glycoprotein substrate Non-substrate 0.6063 P-glycoprotein inhibitor I Non-inhibitor 0.8482 P-glycoprotein inhibitor II Non-inhibitor 0.962 Renal organic cation transporter Non-inhibitor 0.7835 CYP450 2C9 substrate Non-substrate 0.8237 CYP450 2D6 substrate Non-substrate 0.7603 CYP450 3A4 substrate Non-substrate 0.5252 CYP450 1A2 substrate Non-inhibitor 0.8317 CYP450 2C9 inhibitor Non-inhibitor 0.7972 CYP450 2D6 inhibitor Non-inhibitor 0.8991 CYP450 2C19 inhibitor Non-inhibitor 0.8013 CYP450 3A4 inhibitor Non-inhibitor 0.9093 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9377 Ames test Non AMES toxic 0.8524 Carcinogenicity Carcinogens 0.7021 Biodegradation Ready biodegradable 0.9528 Rat acute toxicity 4.3595 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5816 hERG inhibition (predictor II) Non-inhibitor 0.7263
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as tetraalkylammonium salts. These are organonitrogen compounds containing a quaternary ammonium substituted with four alkyl chains.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Quaternary ammonium salts
- Direct Parent
- Tetraalkylammonium salts
- Alternative Parents
- Sulfenyl compounds / Organothiophosphorus compounds / Organopnictogen compounds / Organooxygen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives / Amines / Organic cations
- Substituents
- Tetraalkylammonium salt / Sulfenyl compound / Organothiophosphorus compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organic salt / Organosulfur compound / Organooxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- quaternary ammonium ion, phosphocholines, organic thiophosphate (CHEBI:4753)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Henderson EG, Post-Munson DJ, Reynolds LS, Epstein PM: Echothiophate and cogeners decrease the voltage dependence of end-plate current decay in frog skeletal muscle. J Pharmacol Exp Ther. 1989 Dec;251(3):810-6. [PubMed:2481033]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Peeples ES, Schopfer LM, Duysen EG, Spaulding R, Voelker T, Thompson CM, Lockridge O: Albumin, a new biomarker of organophosphorus toxicant exposure, identified by mass spectrometry. Toxicol Sci. 2005 Feb;83(2):303-12. Epub 2004 Nov 3. [PubMed:15525694]
Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 09:34